NVCR - Is NovoCure a Good Stock to Buy Right Now?
Shares of NovoCure (NASDAQ: NVCR) , a maker of niche medical devices, shot about 68% higher on Jan. 5. Investors were cheering clinical trial results for what could be the company's most important product to date.
Is NovoCure a good stock to buy now, or will its recent gains fizzle out? Here's what you should know before taking any chances with your hard-earned money.
NovoCure develops and markets devices that emit electrical fields in an effort to shrink tumors. The company's lead product at the moment, Optune, is a battery-powered hat that's approved to treat glioblastoma, a form of brain cancer diagnosed roughly 13,000 times per year in the U.S.
For further details see:
Is NovoCure a Good Stock to Buy Right Now?